Resources

1371 Resources for

therapy

Subscribe to this listing via:
RSS
Email

BNET Resources

TomoTherapy to Present at Oppenheimer Healthcare Conference: MADSION, Wis. -- TomoTherapy Incorporated (NASDAQ: TOMO) announced today that Dr. Fred Robertson, CEO, and Steve Hathaway, CFO, will present at the Oppenheimer 19th Annual Healthcare Conference on Monday, November 3, 2008 at 3:20 p.m., ET. The conference is scheduled for November 3-4 at the Waldorf-Astoria Hotel in New York...; Tags: conference, Nasdaq Stock Market Inc., therapy; Research articles 2008-10-27
Compellis Pharmaceuticals, Inc. Awarded Second Broad Patent From the U.S. Patent Office for Novel Obesity Therapy: Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today that they have been issued a second broad patent (7,138,107) by the U.S. Patent and Trademark Office USPTO for its invention entitled "Inhibition of olfactory neurosensory function to treat obesity and related disorders."...; Tags: patent, therapy, U.S. Patent and Trademark Office; Research articles 2008-10-27
Cinryze Receives FDA Approval for Prophylaxis Against Hereditary Angioedema Attacks: -- First and Only C1 Inhibitor Therapy to Be Approved to Prevent Potentially Fatal Condition -- NEW YORK -- Lev Pharmaceuticals, Inc. (OTCBB: LEVP.OB) today announced that the U.S. Food and Drug Administration FDA approved Cinryze[TM] (C1 inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult...; Tags: attack, FDA, patient, SEC, SECURITY, therapy, ViroPharma Inc.; Research articles 2008-10-10
FDA Approves New Injection Site for RISPERDAL® CONSTA® for Schizophrenia Treatment: CAMBRIDGE, Mass. -- Alkermes, Inc. (NASDAQ: ALKS) today announced that patients with schizophrenia now have a new administration option for RISPERDAL([R]) CONSTA([R]) [risperidone Long-Acting Injection]. The U.S. Food and Drug Administration FDA has approved a new injection site, the deltoid muscle in the arm, for RISPERDAL CONSTA for the treatment...; Tags: American Psychiatric Association, FDA, Government, injection, medication, patient, therapy; Research articles 2008-10-09
TomoTherapy to Announce 2008 Third-Quarter Results on Tuesday, October 28: MADISON, Wis. -- TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it will release its 2008 third-quarter results on Tuesday, October 28, 2008 at 3:00 p.m. CDT. TomoTherapy also will hold an investment community conference call on Tuesday, October 28, 2008, beginning at 4:00 p.m. CDT. Fred Robertson, CEO, and...; Tags: Center for Democracy and Technology, Nasdaq Stock Market Inc., therapy; Research articles 2008-10-08

Satellite Healthcare, Providers of Kidney Dialysis and Kidney Disease Services, Honors Founder With Endowed Chair at Stanford University School of Medicine: MOUNTAIN VIEW, Calif. -- Satellite Healthcare, one of the nation's first and largest providers of kidney dialysis services and kidney disease therapies, has honored its founder, Norman S. Coplon, MD, with an endowed chair at Stanford University School of Medicine. The Norman S. Coplon/Satellite Healthcare Professorship in Medicine was...; Tags: Dr., NETWORKING, patient, satellite, Stanford, Stanford University, therapy; Research articles 2008-10-06
Calypso Medical and The University of Pennsylvania Health System Announce Collaboration for Proton Therapy: Project to Integrate Real-Time Tumor Tracking in Proton Therapy SEATTLE & PHILADELPHIA -- Calypso Medical today announced that it has received a $1 million grant from The University of Pennsylvania Health System to develop a compatible version of the Calypso[R] 4D Localization System that would enable real-time tumor tracking...; Tags: collaboration, Company, GPS, radiation, therapy, University of Pennsylvania; Research articles 2008-09-22
EnteroMedics to Present at the Morgan Stanley Global Healthcare Unplugged Conference: ST. PAUL, Minn. -- EnteroMedics Inc. (NASDAQ: ETRM) announced today that Greg S. Lea, Chief Financial Officer, is scheduled to present at the Morgan Stanley Global Healthcare Unplugged Conference in New York, NY on Tuesday, September 9th at 4:30 pm ET. Mr. Lea will provide an overview of the Company...; Tags: HEALTHCARE, Morgan Stanley, patient, therapy; Research articles 2008-09-02
British experts green light Novartis' sight-saving drug: GENEVA AFP — Novartis said Wednesday its Lucentis eye treatment has been recommended by Britain's National Institute for Health and Clinical Excellence NICE as a cost-effective therapy to stave off blindness. The Swiss pharmaceutical giant said in a statement that NICE had recommended Lucentis as "a cost-effective therapy for...; Tags: Agence France-Presse, Britain, Novartis AG, patient, therapy; Research articles 2008-08-27
Medegen Grows Product Distribution Via Co-Marketing Agreement with Bard: MaxPlus[R] Clear[TM] Needleless Access Device Now Available in Bard Peripherally Inserted Central Catheter PICC Kits ONTARIO, Calif. -- Maximus, a business unit of leading infusion therapy firm Medegen Inc., today announced that as a result of a Co-Marketing Agreement between C.R. Bard and Medegen Inc., the MaxPlus[R] Clear[TM] needleless...; Tags: agreement, Clear, infection, Manufacturing, patient, therapy; Research articles 2008-08-18
RaySearch Laboratories AB develops proton therapy system for Uppsala University Hospital: NORDIC BUSINESS REPORT-5 August 2008-RaySearch Laboratories AB develops proton therapy system for Uppsala University HospitalC1994-2008 M2 COMMUNICATIONS LTD http://www.m2.com Swedish medical technology company RaySearch Laboratories AB (OMX Stockholm: RAY B) announced on Tuesday (5 August) that it has landed a new consulting contract from Uppsala University Hospital in Sweden....; Tags: therapy, Uppsala University; Research articles 2008-08-05
Introgen Receives Nasdaq Notice Regarding Minimum Market Value of Listed Securities: AUSTIN, Texas -- Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today announced that on July 30, 2008, it received a letter from The Nasdaq Stock Market ("Nasdaq") indicating that it does not comply with the minimum $50,000,000 market value of listed securities nor the alternative...; Tags: Nasdaq Stock Market Inc., therapy; Research articles 2008-08-01
Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients: COLLEGEVILLE, Pa., & TARRYTOWN, N.Y. -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that the companies have received marketing approval for RELISTOR[TM] methylnaltrexone bromide subcutaneous injection from the European Commission. RELISTOR is now approved in the 27 member states of the...; Tags: Company, Editor, European Commission, HEALTHCARE, patient, Progenics Pharmaceuticals Inc., SOFTWARE, therapy, Wyeth; Research articles 2008-07-03
Mental Health Treatment: It's Commonly Accepted Yet Not So Easy to Obtain or Understand: Younger Adults More Likely to Have Received Treatment; Stigma and Privacy Less of a Concern ROCHESTER, N.Y. -- Seeing a psychologist or other mental health professional isn't an unusual thing; in fact it's relatively common. Nearly three in ten U.S. adults (29%) report that they have received treatment or...; Tags: Benefits, Harris Interactive, HEALTHCARE, SOFTWARE, stigma, therapy; Research articles 2008-07-02
Targeted Therapies to Lead New Wave of Breast Cancer Treatments: PALO ALTO, Calif. -- Rising public awareness about breast cancer and the treatments available has greatly improved revenues in the overall breast cancer therapeutics market. To thrive in this highly competitive market, drug developers must offer drugs that improve survival rates and the quality of life. New analysis from...; Tags: Frost & Sullivan, therapy; Research articles 2008-06-30
EnteroMedics Receives ISO 13485:2003 Certification for the Maestro System: ST. PAUL, Minn. -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it has received ISO 13485:2003 certification from KEMA Quality B.V. for the design, manufacture and distribution of surgical implants and associated accessories for nervous...; Tags: HEALTHCARE, ISO, Quality, therapy; Research articles 2008-06-27
Cadaveric Bone Implants Emerge as Cheaper Alternatives to Metallic Prosthetics in Bone Regeneration Therapy: PALO ALTO, Calif. -- As cadaveric bone implants have the same structural integrity as a normal human bone, they will integrate easily with the body and support the bodily functions well. Since it mimics the normal human bone in its chemical composition, these cadaveric implants, once sterilized and placed inside...; Tags: Frost & Sullivan, integration, mobility, patient, prosthetics, therapy, wheelchair; Research articles 2008-06-23
Pluristem's President & CEO to be Keynote Speaker at The 4th Annual Stem Cells Asia Congress: NEW YORK -- Pluristem Therapeutics Inc. (NASDAQ: PSTI) (DAX: PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized allogeneic cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that Mr. Zami Aberman, Pluristem's President & CEO, will be the keynote speaker at the 4th...; Tags: 3D, CEO, commercialization, Company, president, speaker, therapy, U.S. Congress; Research articles 2008-06-23
New Product Launches Set to Unleash Multiple Growth Avenues in U.S. Monoclonal Antibodies Market: PALO ALTO, Calif. -- The U.S. therapeutic monoclonal antibodies market is poised for a quantum leap with the launch of a multitude of new products and vigorous expansion of therapeutic indications of existing products. A combination of these factors, along with high demand and lack of generic competition, expects to...; Tags: E-mail, Frost & Sullivan, Government, patient, therapy; Research articles 2008-06-09
Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-On Therapy Studies: Results from five pivotal phase 3 studies of alogliptin were announced today at the American Diabetes Association ADA 68th Scientific Sessions by Takeda Global Research & Development Center, Inc. Alogliptin, which has been shown to be a highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4), is currently under investigation as...; Tags: American Diabetes Association, baseline, patient, therapy; Research articles 2008-06-07